Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2013 Aug;13(4):550-9.
doi: 10.1007/s11892-013-0381-0.

Uric acid lowering to prevent kidney function loss in diabetes: the preventing early renal function loss (PERL) allopurinol study

David M Maahs  1 , Luiza Caramori, David Z I Cherney, Andrzej T Galecki, Chuanyun Gao, Diana Jalal, Bruce A Perkins, Rodica Pop-Busui, Peter Rossing, Michael Mauer, Alessandro Doria; PERL Consortium
Collaborators, Affiliations
Review

Uric acid lowering to prevent kidney function loss in diabetes: the preventing early renal function loss (PERL) allopurinol study

David M Maahs et al. Curr Diab Rep. 2013 Aug.

Abstract

Diabetic kidney disease causes significant morbidity and mortality among people with type 1 diabetes (T1D). Intensive glucose and blood pressure control have thus far failed to adequately curb this problem and therefore a major need for novel treatment approaches exists. Multiple observations link serum uric acid levels to kidney disease development and progression in diabetes and strongly argue that uric acid lowering should be tested as one such novel intervention. A pilot of such a trial, using allopurinol, is currently being conducted by the Preventing Early Renal Function Loss (PERL) Consortium. Although the PERL trial targets T1D individuals at highest risk of kidney function decline, the use of allopurinol as a renoprotective agent may also be relevant to a larger segment of the population with diabetes. As allopurinol is inexpensive and safe, it could be cost-effective even for relatively low-risk patients, pending the completion of appropriate trials at earlier stages.

PubMed Disclaimer

Conflict of interest statement

The authors have no conflicts of interest to disclose.

Disclosure

David M. Maahs declares that he has no conflict of interest.

M. Luiza Caramori declares that she has no conflict of interest.

David Z.I. Cherney declares that he has no conflict of interest.

Andrzej T. Galecki declares that he has no conflict of interest.

Chuanyun Gao declares that she has no conflict of interest.

Diana Jalal has received ASN honoraria for speaking on the role of uric acid in kidney and cardiac disease in the elderly.

Bruce A. Perkins is a Senior Advisory Board Member for Neurometrix Inc.; and has been a Site investigator for a sponsored clinical trial for Medtronic Inc.; a Co-PI for a sponsored clinical trial by Boehringer Ingelheim; and has received speaker honoraria from Medtronic Inc., Roche, GlaxoSmithKline, Johnson & Johnson, Novo Nordisk, and Eli Lilly.

Rodica Pop-Busui declares that she has no conflict of interest.

Peter Rossing serves on the board for Astra Zeneca/BMS, Eli Lilly, Janssen, Novo Nordisk, and Astellas; has received grant support from Novo Nordisk, Novartis, and Abbott; has received payment for lectures including service on speakers bureaus from Astra Zeneca/BMS, Novartis, and Sanofi-Aventis; and has stock/stock options with Novo Nordisk.

Michael Mauer declares that he has no conflict of interest.

Alessandro Doria has received research grant support from Sanofi-Aventis; has received travel/accommodations expenses covered or reimbursed from the American Society of Nephrology and the Italian Society of Diabetology.

Figures

Figure 1
Figure 1
Mechanisms through which increased uric acid may contribute to the development of diabetic nephropathy.
See this image and copyright information in PMC

Similar articles

  • Preventing Early Renal Loss in Diabetes (PERL) Study: A Randomized Double-Blinded Trial of Allopurinol-Rationale, Design, and Baseline Data.
    Afkarian M, Polsky S, Parsa A, Aronson R, Caramori ML, Cherney DZ, Crandall JP, de Boer IH, Elliott TG, Galecki AT, Goldfine AB, Haw JS, Hirsch IB, Karger AB, Lingvay I, Maahs DM, McGill JB, Molitch ME, Perkins BA, Pop-Busui R, Pragnell M, Rosas SE, Rossing P, Senior P, Sigal RJ, Spino C, Tuttle KR, Umpierrez GE, Wallia A, Weinstock RS, Wu C, Mauer M, Doria A; PERL Study Group. Afkarian M, et al. Diabetes Care. 2019 Aug;42(8):1454-1463. doi: 10.2337/dc19-0342. Epub 2019 Jun 11. Diabetes Care. 2019. PMID: 31186299 Free PMC article. Clinical Trial.
  • Uric Acid and Diabetic Nephropathy Risk.
    Mauer M, Doria A. Mauer M, et al. Contrib Nephrol. 2018;192:103-109. doi: 10.1159/000484284. Epub 2018 Jan 23. Contrib Nephrol. 2018. PMID: 29393137 Free PMC article. Review.
  • Serum Urate Lowering with Allopurinol and Kidney Function in Type 1 Diabetes.
    Doria A, Galecki AT, Spino C, Pop-Busui R, Cherney DZ, Lingvay I, Parsa A, Rossing P, Sigal RJ, Afkarian M, Aronson R, Caramori ML, Crandall JP, de Boer IH, Elliott TG, Goldfine AB, Haw JS, Hirsch IB, Karger AB, Maahs DM, McGill JB, Molitch ME, Perkins BA, Polsky S, Pragnell M, Robiner WN, Rosas SE, Senior P, Tuttle KR, Umpierrez GE, Wallia A, Weinstock RS, Wu C, Mauer M; PERL Study Group. Doria A, et al. N Engl J Med. 2020 Jun 25;382(26):2493-2503. doi: 10.1056/NEJMoa1916624. N Engl J Med. 2020. PMID: 32579810 Free PMC article. Clinical Trial.
  • Effects of Allopurinol on the Progression of Chronic Kidney Disease.
    Badve SV, Pascoe EM, Tiku A, Boudville N, Brown FG, Cass A, Clarke P, Dalbeth N, Day RO, de Zoysa JR, Douglas B, Faull R, Harris DC, Hawley CM, Jones GRD, Kanellis J, Palmer SC, Perkovic V, Rangan GK, Reidlinger D, Robison L, Walker RJ, Walters G, Johnson DW; CKD-FIX Study Investigators. Badve SV, et al. N Engl J Med. 2020 Jun 25;382(26):2504-2513. doi: 10.1056/NEJMoa1915833. N Engl J Med. 2020. PMID: 32579811 Clinical Trial.
  • Serum uric acid as a new player in the development of diabetic nephropathy.
    Hovind P, Rossing P, Johnson RJ, Parving HH. Hovind P, et al. J Ren Nutr. 2011 Jan;21(1):124-7. doi: 10.1053/j.jrn.2010.10.024. J Ren Nutr. 2011. PMID: 21195935 Review.
See all similar articles

Cited by

See all "Cited by" articles

References

    1. Marshall SM. Diabetic nephropathy in type 1 diabetes: has the outlook improved since the 1980s? Diabetologia. 2012;55(9):2301–6. - PubMed
    1. Nathan DM, Zinman B, Cleary PA, et al. Modern-day clinical course of type 1 diabetes mellitus after 30 years’ duration: the diabetes control and complications trial/epidemiology of diabetes interventions and complications and Pittsburgh epidemiology of diabetes complications experience (1983–2005) Arch Intern Med. 2009;169(14):1307–1316. - PMC - PubMed
    1. Krolewski AS, Bonventre JV. High risk of ESRD in type 1 diabetes: new strategies are needed to retard progressive renal function decline. Semin Nephrol. 2012;32(5):407–414. Review highlighting the need for new strategies and novel therapeutics to prevent renal function decline. - PMC - PubMed
    1. Maahs DM, Rewers M. Editorial: Mortality and renal disease in type 1 diabetes mellitus--progress made, more to be done. J Clin Endocrinol Metab. 2006;91(10):3757–3759. - PubMed
    1. de Boer I, Rue TC, Hall YN, Heagerty PJ, Weiss NS, Himmelfarb J. Temporal trends in the prevalence of diabetic kidney disease in the United States. JAMA. 2011;305(24):2532–2539. Overview of prevalence of DKD in the US and demonstrates continued burden of diabetic kidney disease on individuals and its public health importance. - PMC - PubMed

Publication types

MeSH terms